Phage enzyme is a formidable force

Abstract

Interest in the use of bacteriophage for combating bacterial infections has experienced a resurgence in recent years concomitant with the rise in antibiotic resistance. Phage therapy research has received a boost from recent studies from Rockefeller University on a potent anti-streptococcal enzyme harvested from a bacteriophage. As reported in PNAS, the lysin enzyme lyses the cell walls of Group A streptococci, resulting in cell death. Study leader Vincent Fischetti says that the enzyme is unlikely to clear streptococcal infections, but could be used prophylactically without disturbing other microflora. For example, daily doses of the enzyme could be used to stop the spread of strep throat amongst military personnel or children in daycare centres and schools. The enzyme, which could potentially be made artificially at a very low cost, might also prove to be an effective weapon against ear infections and necrotizing fasciitis. AV (http://www.pnas.org)